



cancers



an Open Access Journal by MDPI

Advances in Prognosis and Theranostics of Lung Cancer

Guest Editors:

Dr. Sudip Mukherjee

Department of Bioengineering,
Rice University, 6500 Main Street,
Houston, TX 77005, USA

Dr. Manash Paul

Division of Pulmonary and
Critical Care Medicine, David
Geffen School of Medicine, The
University of California, Los
Angeles (UCLA), Los Angeles, CA
90095, USA.

Deadline for manuscript
submissions:

closed (31 December 2021)

Message from the Guest Editors

Dear Colleagues,

Lung cancer is one of the leading causes of cancer-related death worldwide. As per the recent cancer statistics data, lung cancer accounts for an estimated 2.1 million lung cancer cases and 1.8 million deaths in 2018. Lung cancer recurs following surgery in approximately 30% of patients and therefore has long been the number-one cause of death from cancer.

Hence alternative prognostic, therapeutic, and diagnostic approaches are required to reduce overall mortality and improve patient quality of life. In this present issue, we will publish research, reviews, and short communications on the modern approaches to combat lung cancer. Contributions on biomarker discovery, diagnosis, therapeutic modalities including immunotherapy, cancer vaccines, biomaterials-based theranostics approaches, nanomedicine-based theranostics, small molecule-based targeting, immunomodulatory approaches and other emergent approaches in precision oncology are also encouraged.

Dr. Sudip Mukherjee
Dr. Manash Paul
Guest Editors



mdpi.com/si/57796

Special Issue



cancers



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
X@Cancers_MDPI